NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.67▼$4.9050-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume350,907 shsAverage Volume373,201 shsMarket Capitalization$149.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. EDGE Stock News HeadlinesMarch 18, 2024 | finance.yahoo.comBrenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 ConferenceMarch 15, 2024 | finanznachrichten.deMonoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarketsMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. March 15, 2024 | msn.comPioneering Protein Design A New Frontier in COVID-19 TherapeuticsMarch 14, 2024 | finance.yahoo.comLeading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine InnovationMarch 13, 2024 | finance.yahoo.comPrime Therapeutics and Capital Rx Enter Into Transformative Strategic AllianceMarch 11, 2024 | markets.businessinsider.comPromising Future for Kymera Therapeutics: Analyst Endorses ‘Buy’ on Innovative Protein Degradation CompoundsMarch 8, 2024 | finance.yahoo.comPromontory Therapeutics Enrolls 109 Patients in Prostate Cancer StudyMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 7, 2024 | finance.yahoo.comKyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple SclerosisMarch 6, 2024 | finance.yahoo.comFierce Medtech Names Genesis Therapeutics a "Fierce 15" Company of 2023March 5, 2024 | finance.yahoo.comSonata Therapeutics and the Champalimaud Foundation Announce Research Collaboration for SNT-3012 in Pancreatic and Colorectal CancersMarch 5, 2024 | finance.yahoo.comAthos Therapeutics Announces the Autonomization of their Artificial Intelligence and Machine Learning PlatformsMarch 5, 2024 | msn.comBetter Weight Loss Drug Stock: Viking Therapeutics vs. Eli LillyMarch 4, 2024 | msn.comMilestone marked as 200th company commits to Scottish EDGE PledgeFebruary 28, 2024 | finance.yahoo.comBlue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor ConferenceFebruary 26, 2024 | msn.comUS Stocks Edge Higher; Domino's Posts Upbeat EarningsFebruary 22, 2024 | markets.businessinsider.comRAJANT HEALTH’S CUTTING-EDGE WEARABLE RECEIVES MEDICAL EXPERT ENDORSEMENTSFebruary 16, 2024 | marketwatch.comHealth-Care Stocks Edge Higher -- Health Care RoundupFebruary 16, 2024 | finance.yahoo.comGlobal Non Hodgkin Lymphoma Therapeutics Market Predicted to Reach $16.8 Billion by 2030 at a CAGR of 8.4%February 15, 2024 | msn.com'I don't want pretty' - Relief and rejoicing as Stoke City edge QPR clashFebruary 14, 2024 | msn.comPrelude Therapeutics moves into new 100,000 square foot headquartersFebruary 13, 2024 | msn.comMicrosoft’s new Outlook requires you to have Edge installedFebruary 12, 2024 | finance.yahoo.comPolaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic woundsFebruary 8, 2024 | finance.yahoo.comHere's Why We're Watching Arovella Therapeutics' (ASX:ALA) Cash Burn SituationFebruary 8, 2024 | msn.comEdge of Ember Collaborates With Charlotte Collins on ‘70s-inspired Jewelry CollectionFebruary 8, 2024 | uk.finance.yahoo.comGlobal Melanoma Therapeutics Market Set for Remarkable Growth, Projected to Reach $6.16 Billion by 2028See More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today3/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book5.01Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$149.83 million OptionableNot Optionable Beta3.65 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsI-MabNASDAQ:IMABEmergent BioSolutionsNYSE:EBSCytomX TherapeuticsNASDAQ:CTMXNektar TherapeuticsNASDAQ:NKTRSyros PharmaceuticalsNASDAQ:SYRSView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.